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RENAL DISEASE IN RACIAL AND ETHNIC MINORITY GROUPS
Introduction
In the fall of 2001, in the shadow of ‘nine-eleven,’ a effort with the available resources. The third group in-
group of nephrologists from around the world met in cludes articles on the current status of programs for the
Santa Fe, New Mexico. Over two days they learned of the management of end-stage disease in nine different racial
outcomes of epidemiological, clinical, and basic science groups from around the world. As a result of increased
studies and discussed the burgeoning problems relating surveillance over the last decade, few now doubt that re-
to progressive renal disease that beset racial and ethnic nal disease is occurring in epidemic proportions through-
minority groups worldwide. As the assembled group com- out the developing world. As demonstrated in developed
prised basic scientists, clinicians, fellows in training, and countries, renal disease tends to be clinically ‘silent’ and,
physicians and health workers who operate on the front therefore, goes largely unnoticed, as those who have
lines, not the least important feature of the meeting was contracted it are not likely to seek medical advice. A
the rare opportunity for people to bypass the traditional strong causal association with diabetes in many ethnic
and somewhat daunting boundaries of health practice minorities and the lethal cardiovascular complications
and to meet to share experiences. tend to lead to an underestimation of the primary impor-
This Supplement contains all but a few of the papers tance of renal disease and, hence, under-reporting in
that were presented at the meeting, and while they could official mortality statistics. This under-reporting is likely
reasonably be described as an eclectic collection, they to reduce the priority afforded to research studies in this
do represent the state of the art in this field. They are field. Furthermore, the poorer the country, in economic
divided into three sections. terms, the greater is the likely prevalence and incidence
The first section groups together those presentations of renal disease, and the less likely that any resources
that discuss the etiology and pathogenesis of renal dis- will be available.
ease in racial and ethnic minorities. That the majority Governor Bowerkaty of the Zuni people, one of the
of the articles in this section describe work carried out indigenous tribes of the New Mexico, spoke eloquently
in African American and American Indian populations of the problems that the Zuni face. They perceive that
reflects the deficiency of studies on this topic in most many prior researchers across a range of disciplines have
parts of the developing world. Of particular interest is not taken the people into their confidence, not shared
the paper by Hoy and colleagues, which represents early their results, and not been prepared to recognize the value
work in the difficult task of questioning the relationship of intellectual property rights; more research degrees have
between a low nephron number and the subsequent de- been awarded than health advances achieved! This is a
velopment of renal failure. The second section includes particularly important issue when studies are likely to
articles that explore the prevention and treatment of be ongoing over a period of years, and when they involve
renal disease, with a focus both on clinical trials, and the assessment of the contribution of genetic endowment to
management of end-stage disease by the modalities of disease. The Governor stated that in the future those who
dialysis and renal transplantation. Of special interest are wish to conduct research are likely to have their propos-
the articles by Rizvi et al, Ramirez et al, and by Mani. als independently assessed, and the nature of research
The first is inspiring in showing what can be achieved contracts subjected to legal review. He concluded that
in a developing country by a dedicated team approach renal disease research remains a major research priority
toward the problem of renal transplantation. While Sin- for the Zuni because of the great human and economic
gapore is by no means a poor country, the second paper, burden that kidney diseases impose.
by Ramirez et al describes in depth how an active renal How then is the problem to be tackled? Clearly with
treatment program can be built and financed in a country the majority of the world’s nephrologists living and work-
that does not publicly support the full cost of treating ing far from those parts of the world where perhaps
renal failure. Mani describes, in a passionately written three quarters of the world’s patients with renal disease
paper, a method for the investigation and treatment of
live, there are not going to be sufficient resources avail-
renal disease in rural India, which is particularly impor-
able to manage the disease, particularly, end-stage renaltant as it recognizes very clearly the need to match the
disease. In many parts of the world such treatment is
only available to the wealthy, and to those fortunate
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and cooperative public health approach would certainly sufficient evidence to promote treatment programs using
these agents, though their use in developing countries isespouse the need to embrace such basic requirements
as clean water, good sanitation, vaccination programs, not going to be without its problems, particularly with
regard to cost factors, and perhaps to concerns regardingand good antenatal care to assist in combating the many
the use of this class of agents in young fertile women.afflictions contributing to the high rates of renal disease.
There is no reason why epidemiological studies and treat-It is at the same time essential to continue to gather
ment programs should not run in a combined fashion,evidence leading to accurate documentation of the prev-
as Hoy and colleagues illustrate in this issue. It is clear,alence and incidence of chronic renal disease, and where
though, that progress will not accelerate until and unlessthese are seen to be high, to study potential etiologic fac-
the world in general—and the nephrological communitytors and pathogenetic mechanisms. The nature of medi-
in particular—amplify their commitment.cal practice and the lack of resources in many of these
This conference was supported by the American Soci-areas mean that there will have to be, of necessity, a
ety of Nephrology, International Society of Nephrology,transfer of resources and technology to achieve even the
National Institutes of Health, and the National Kidneysimplest of these goals. A focus on diabetes among many
Foundation. Unrestricted grants generously provided byracial and ethnic minority groups is an imperative, and
Pfizer, Merck, and Ortho Biotech permitted the estab-in sub-Saharan Africa it is clear that hypertension plays
lishment of a scholarship program that allowed us toa powerful role, though its precise contribution to the
invite young investigators to attend the meeting. Thedevelopment and progression of chronic renal disease
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